In 1987, an editorial accompanying a report on the use of high-doseinterleukin-2 therapy for cancer asked whether the field ofimmunotherapy was at "the beginning of the end" or "the endof the beginning."1 In retrospect, I would say it was at the"beginning of the beginning." Have we made progress since then?Finn, in her review of tumor immunology in this issue of theJournal (pages 2704–2715), answers emphatically in theaffirmative, and the report by Hunder et al., also in this issue(pages 2698–2703), underscores the remarkable potentialof the immune system to eradicate cancer, even when . . . [Full Text of this Article]
Source Information
Dr. Weiner is director of the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
Related Letters:
Cancer Immunotherapy
Rosenberg S. A., Dudley M. E., Restifo N. P., Prestwich R., Vile R., Melcher A., Weiner L. M.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1072-1073, Sep 4, 2008.
Correspondence
This article has been cited by other articles:
Schetter, A. J., Nguyen, G. H., Bowman, E. D., Mathe, E. A., Yuen, S. T., Hawkes, J. E., Croce, C. M., Leung, S. Y., Harris, C. C.
(2009). Association of Inflammation-Related and microRNA Gene Expression with Cancer-Specific Mortality of Colon Adenocarcinoma. Clin. Cancer Res.
15: 5878-5887
[Abstract][Full Text]
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., Weber, J.
(2009). PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int Immunol
21: 1065-1077
[Abstract][Full Text]
Maes, W., Rosas, G. G., Verbinnen, B., Boon, L., De Vleeschouwer, S., Ceuppens, J. L., Van Gool, S. W.
(2009). DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol Duke
11: 529-542
[Abstract][Full Text]
Rosenberg, S. A., Dudley, M. E., Restifo, N. P., Prestwich, R., Vile, R., Melcher, A., Weiner, L. M.
(2008). Cancer immunotherapy.. NEJM
359: 1072-1072
[Full Text]